激素抵抗性哮喘的研究进展

Study progression of steroid-resistant asthma

支气管哮喘的本质是气道慢性非特异性炎症,肾上腺糖皮质激素抗炎治疗已成为哮喘现代治疗的主要方法。但约5%-10%的患者对激素治疗不敏感而成为难治性哮喘,这种对激素治疗效果较差的哮喘被称为“激素抵抗性哮喘”（steroid-resistant asthma,SRA）。其发生机制不明,可能与糖皮质激素受体β、基因表达和热休克蛋白异常等有关,免疫和非免疫治疗可以改善哮喘症状。

The nature of asthma is glucocorticosteroid has been the main modern the non-specificity inflammation in airway, using adrenal therapy for it. But about 5%-10% patients are insensitive to adrenal glucocorticosteroid therapy and aggravate into difficult asthma. This kind of asthma which has bad therapeutic efficacy response to adrenal glucocorticosteroid is named steroid-resistant asthma （SRA）. Its pathogenesis is unknown,but it is concerned with human glucocorticoid receptor β（hGRβ）, gene expression and heat-shock protein（HSP） et al. Immunotherapy and nonimmune therapy can relieve patients＇ asthmatic symptoms.